Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab
Abstract The combination of toripalimab (an anti-PD-1 antibody) with definitive chemoradiotherapy (CRT) demonstrated encouraging efficacy against locally advanced esophageal squamous cell carcinoma (ESCC) in the EC-CRT-001 phase II trial (NCT04005170). The primary endpoint of this trial was the clin...
Main Authors: | Baoqing Chen, Shiliang Liu, Yujia Zhu, Ruixi Wang, Xingyuan Cheng, Biqi Chen, Mihnea P. Dragomir, Yaru Zhang, Yonghong Hu, Mengzhong Liu, Qiaoqiao Li, Hong Yang, Mian Xi |
---|---|
格式: | 文件 |
语言: | English |
出版: |
Nature Portfolio
2024-03-01
|
丛编: | Nature Communications |
在线阅读: | https://doi.org/10.1038/s41467-024-46307-7 |
相似书籍
-
Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trialResearch in context
由: Ruixi Wang, et al.
出版: (2024-09-01) -
A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)Research in context
由: Rui Chen, et al.
出版: (2023-08-01) -
Prognostic value of immuno-inflammatory biomarkers in esophageal squamous cell carcinoma patients receiving immunotherapy combined with chemoradiotherapy and its association with immuno-genomic landscape
由: Xingyuan Cheng, et al.
出版: (2024-12-01) -
Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial
由: Hui Jiang, et al.
出版: (2023-09-01) -
M1A and m7G modification-related genes are potential biomarkers for survival prognosis and for deciphering the tumor immune microenvironment in esophageal squamous cell carcinoma
由: Ruixi Wang, et al.
出版: (2023-06-01)